GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Operating Margin %

Cognition Therapeutics (Cognition Therapeutics) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cognition Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-9.19 Mil. Cognition Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Cognition Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Cognition Therapeutics's Operating Margin % or its related term are showing as below:


CGTX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -161.26
* Ranked among companies with meaningful Operating Margin % only.

Cognition Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cognition Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-9.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-29.56 Mil.


Cognition Therapeutics Operating Margin % Historical Data

The historical data trend for Cognition Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Operating Margin % Chart

Cognition Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
- - - - -

Cognition Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cognition Therapeutics's Operating Margin %

For the Biotechnology subindustry, Cognition Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognition Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's Operating Margin % falls into.



Cognition Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cognition Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-25.919 / 0
= %

Cognition Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-9.19 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognition Therapeutics  (NAS:CGTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cognition Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognition Therapeutics (Cognition Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
John Brendan Doyle officer: Chief Financial Officer C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi director, officer: CEO & President C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano officer: Chief Medical Officer C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone director C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace director C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107

Cognition Therapeutics (Cognition Therapeutics) Headlines

From GuruFocus